SCHEMBL95511

SCHEMBL95511

C/C(=N\c1ccccc1NC(=O)C(C)(C)N1C(C)(C)C(C)(C)C(C)(C)C1(C)C)c1ccc(Cl)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GLA P06280 2/20 0.40
USP2 O75604 1/20 0.40
MAPT P10636 1/20 0.40
TSHR P16473 1/20 0.40
NPC1 O15118 5/20 0.37
RAB9A P51151 5/20 0.37
LMNA P02545 3/20 0.37
PKM P14618 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
ALDH1A1 P00352 3/20 0.36
KDM4E B2RXH2 2/20 0.36
POLB P06746 1/20 0.36
MEN1 O00255 3/20 0.35
KMT2A Q03164 3/20 0.35
TP53 P04637 2/20 0.35
CYP1A2 P05177 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
GAA P10253 1/20 0.35
MDM4 O15151 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL94957 0.76 GLA (0.37) GLAUSP2MAPTTSHRNPC1
SCHEMBL95523 0.72 HDAC1 (0.44) NPC1RAB9AMAPK1PDK1PDK2
SCHEMBL95406 0.68 PDK1 (0.59) MAPTNPC1RAB9ALMNAALDH1A1
SCHEMBL16123674 0.62 NOS3 (0.47) MAPTNPC1RAB9ALMNASMN1; SMN2
SCHEMBL15136962 0.60 LMNA (0.48) MAPTNPC1RAB9ALMNASMN1; SMN2
SCHEMBL28048814 0.60 LMNA (0.66) MAPTNPC1RAB9ALMNASMN1; SMN2
SCHEMBL15136964 0.60 LMNA (0.48) MAPTNPC1RAB9ALMNASMN1; SMN2
SCHEMBL15073407 0.60 LMNA (0.49) MAPTTSHRNPC1RAB9ALMNA
SCHEMBL31285549 0.60 LMNA (0.49) MAPTTSHRNPC1RAB9ALMNA
SCHEMBL20846651 0.59 EPHX2 (0.51) TSHRNPC1RAB9ALMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120058085-A1 Deuterium Modified Benzimidazoles CONCERT PHARMACEUTICALS, INC. 2012-03-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120058085-A1 Deuterium Modified Benzimidazoles POLRMT, EIF2AK2, DUT GLA 3638/4885USP2 2671/4885MAPT 4232/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.